Editorial: HBeAg seroconversion is not sufficient to allow cessation of nucleos(t)ide analogue treatment in Caucasian hepatitis B patients.
Ingiliz, P
Editorial: HBeAg seroconversion is not sufficient to allow cessation of nucleos(t)ide analogue treatment in Caucasian hepatitis B patients. [electronic resource] - Alimentary pharmacology & therapeutics 06 2018 - 1551-1552 p. digital
Publication Type: Editorial; Comment
1365-2036
10.1111/apt.14649 doi
Fatal Outcome
Hepatitis B
Hepatitis B e Antigens
Hepatitis B, Chronic
Humans
Recurrence
Seroconversion
Editorial: HBeAg seroconversion is not sufficient to allow cessation of nucleos(t)ide analogue treatment in Caucasian hepatitis B patients. [electronic resource] - Alimentary pharmacology & therapeutics 06 2018 - 1551-1552 p. digital
Publication Type: Editorial; Comment
1365-2036
10.1111/apt.14649 doi
Fatal Outcome
Hepatitis B
Hepatitis B e Antigens
Hepatitis B, Chronic
Humans
Recurrence
Seroconversion